@article{1522dc659d1346b0bb9b4c21b9cab6a8,
title = "The Japanese Breast Cancer Society Clinical Practice Guidelines for systemic treatment of breast cancer, 2018 edition",
abstract = "Purpose: We present the English version of The Japanese Breast Cancer Society (JBCS) Clinical Practice Guidelines for systemic treatment of breast cancer, 2018 edition. Methods: The JBCS formed a task force to update the JBCS Clinical Practice Guidelines, 2015 edition, according to Minds Handbook for Clinical Practice Guideline Development 2014. First, we set multiple outcomes for each clinical question (CQ). Next, quantitative or qualitative systematic review was conducted for each of the multiple outcomes, and the strength of recommendation for the CQ was taken into consideration during meetings, with the aim of finding a balance between benefit and harm. Finalized recommendations from each session were confirmed through discussion and voting at the recommendation decision meeting. Results: The recommendations, the strength of recommendation and the strength of evidence were determined based on systemic literature reviews and the meta-analyses for each CQ. Conclusion: The JBCS updated the Clinical Practice Guidelines for systemic treatment of breast cancer.",
keywords = "Breast cancer, Guideline, Systemic treatment",
author = "Tatsunori Shimoi and Nagai, {Shigenori E.} and Tetsuhiro Yoshinami and Masato Takahashi and Hitoshi Arioka and Mikiya Ishihara and Yuichiro Kikawa and Kei Koizumi and Naoto Kondo and Yasuaki Sagara and Masahiro Takada and Toshimi Takano and Junji Tsurutani and Yoichi Naito and Rikiya Nakamura and Masaya Hattori and Fimikata Hara and Naoki Hayashi and Toshiro Mizuno and Minoru Miyashita and Nami Yamashita and Takashi Yamanaka and Shigehira Saji and Hiroji Iwata and Tatsuya Toyama",
note = "Funding Information: T. Toyama received research funding from Chugai, Novartis Pharma and Eisai, and honoraria from AstraZeneca. MT received research funding from Eisai, Kyowa Kirin, Nippon Kayaku and Taiho and honoraria from AstraZeneca, Eisai, Eli Lilly and Pfizer. KK received honoraria from Pfizer, Chugai, Eisai, Eli Lilly, Novartis Pharma, AstraZeneca, Merck Serono, Genomic Health, Allergan Japan, Kyowa Kirin, Daiichi Sankyo, and Taiho. HA received honoraria from Novartis Pharma, Taiho, Nippon Kayaku, Chugai, MSD, Takeda, Sanofi, Ono, Pfizer, Eisai, Kyowa Kirin and Mochida, and research funds from Taiho, Chugai and Kyowa Kirin. MT received honoraria from Chugai, AstraZeneca, Pfizer, Eli Lilly, Eisai, Daiichi Sankyo, and Kyowa Kirin, and research funding from AstraZeneca, Eisai, and Daiichi Sankyo. T. Takano received research funding from Daiichi Sankyo, Kyowa Kirin, Eisai, Ono, Bristol-Myers Squibb, MSD, Merck Serono, Taiho, Novartis Pharma, and Chugai, and honoraria from Daiichi Sankyo, Kyowa Kirin, Eisai, Pfizer, and Eli Lilly. YN received honoraria from Pfizer, Chugai, Eisai, Eli Lilly, Taiho, Fuji film, Toyama Kagaku, Novartis Pharma, Nippon Kayaku, AstraZeneca, Merck Serono, Bayer, Roche, and Meiji Seika, and research funding from Roche Merck Serono, AstraZeneca, Eli Lilly, Nippon Kayaku, Pfizer, and Taiho. TY received honoraria from Chugai Pharma, Kyowa Kirin, Novartis Pharma, and Pfizer. NK reports honoraria from Chugai, AstraZeneca, Eisai, Pfizer, and Novartis Pharma. MI received honoraria from Chugai, Eisai, Pfizer, MSD, and Takara Bio. YK received honoraria from Eisai, Novartis Pharma, Pfizer, Chugai, AstraZeneca, and Taiho. SN received honoraria from Chugai, Novartis Pharma, Pfizer, Eli Lilly, Eisai, and Taiho and research funding from Chugai and Nippon Kayaku. TY received honoraria from Eisai, Chugai, Daiichi Sankyo, Novartis Pharma, Pfizer, and Taiho. SS received honoraria from Eisai, Chugai, Astra Zeneca, Takeda, Novartis Pharma, Taiho, Kyowa Kirin, Pfizer, Daiichi Sankyo, Nihon Kayaku, and Ono and research funding from Eisai, Chugai, Astra Zeneca, Takeda, Taiho and Ono. SS is the executive board member of JBCS and JBCRG. HI received honoraria from Chugai, Astra Zeneca, MDS, Novartis Pharma, Kyowa Kirin, Pfizer, Daiichi Sankyo, and Eli Lilly and research funding from Chugai, Novartis Pharma, MDS, and Eli Lilly. The other authors declare no relevant conflicts of interest. Funding Information: We thank Prof. Masahiro Yoshida of International University of Health and Welfare, and Japan Council for Quality Health Care for his excellent advice; Mrs. Fujimi Kawai of The Japan Medical Library Association for her high-grade literature search; Mrs. Hitomi Sasaki and Kazuyo Uno of Kanehara & Co., Ltd. for their excellent assistance; and Marla Brunker, from Edanz Group (https://www.edanzediting.com/ac), for editing a draft of this manuscript. Publisher Copyright: {\textcopyright} 2020, The Japanese Breast Cancer Society.",
year = "2020",
month = may,
day = "1",
doi = "10.1007/s12282-020-01085-0",
language = "English",
volume = "27",
pages = "322--331",
journal = "Breast Cancer",
issn = "1340-6868",
publisher = "Springer Japan",
number = "3",
}
